Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Sequencing Tool Looks for Genetic Alterations in Childhood Cancer

By Drug Discovery Trends Editor | February 11, 2009

A researcher at St. Jude’s Research Hospital is the recipient of the “What Would You Do With a $10K Genome” grant program, sponsored by Applied Biosystems, a division of Life Technologies Corporation. This program was created to inspire new scientific approaches that employ advanced genomic technologies that are now enabling human genomes to be sequenced for as little as $10,000. Charles Mullighan, MD, PhD, of St. Jude Children’s Research Hospital received the first-prize award at the 10th annual Advances in Genome Biology and Technology meeting in Marco Island, Florida.

Mullighan, an assistant member in the Department of Pathology at St. Jude, was selected from more than 200 entries based upon his interest in using a next-generation sequencing approach to identify potential new therapeutic opportunities related to acute lymphoblastic leukemia, which is a cancer of white blood cells. It is the most common form of childhood cancer, affecting one in 29,000 children annually.

Despite the dramatic increases in cure rates over the last few decades, 15% of children affected by this disease each year will relapse. For those who do relapse, only 30% will survive five years. In an effort to increase cure rates further, Mullighan and his team will use Applied Biosystems’ SOLiD 3 System, a genomic analysis platform, to develop a better understanding of the genetic abnormalities contributing to leukemia relapse, and to also identify suitable molecular targets for novel therapies. The research study involves the sequencing of samples from five pediatric patients treated at St. Jude. The patients’ samples were taken at three different time points, including normal tissue (germline), leukemia cells obtained at diagnosis, and at relapse.

“To improve the outcome of relapsed acute lymphoblastic leukemia, we must identify all mutations contributing to treatment failure,” said Dr. Mullighan. “The comprehensive identification of genetic changes in tumor cells is a major goal of cancer research, and this grant provides a tremendous opportunity to look across the genome and identify all coding mutations in this disease. Ultimately, our aim is to use this genetic information to identify new pathways and targets for therapy in relapsed acute lymphoblastic leukemia.”

As part of winning the first-prize grant, researchers from Applied Biosystems will work collaboratively with Mullighan to generate 60 gigabases or 750 million tags of sequencing data for this research project. Applied Biosystems will also perform all sample processing, data generation, and primary data analysis using the SOLiD 3 System. Researchers will be able to detect structural variation in the genome such as novel single-base changes, or SNPs, large and small insertion/deletions, translocations and copy number variants.

“Next-generation sequencing is helping to accelerate scientific research by providing advanced genomic solutions that will identify biological targets that will ultimately lead to the development of genetic-based therapeutics,” said Mark Stevenson, President and Chief Operating Officer of Life Technologies. “The grant program provides a collaborative opportunity to accelerate research Dr. Mullighan and other scientists at the St. Jude Children’s Research Hospital have already begun to ultimately advance genetic therapeutics for complex disease.”

Date: February 2, 2009
Source: Applied Bisosystems,a division of Life Technologies Corporation 


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE